Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies, has filed IND (Investigational New Drug) application for anti diabetic and anti obesity drug with Drugs Controller General of India (DCGI).
Speaking on the new development, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus Cadila, said, “The discovery of the novel GLP-1 agonist, ZYD1, using our discovery platform technology is an important achievement for us. We believe that it holds promising commercial potential as a best-in-class candidate due to unmet medical needs in the treatment of diabetes.”
Zydus Cadila announced the filing of the IND application for ZYD1 – a novel GLP-1 agonist molecule with the DCGI. Designed and developed at the Zydus Research Centre, ZYD1 is a novel candidate in the class of antidiabetic agents known as incretin mimetics and has displayed a better efficacy and safety profile.
Incretin mimetics are poised to dominate the future of anti-diabetic therapy and presents a huge opportunity in bridging unmet medical needs that still continues to dodge the treatment and care of diabetes. The new class of drugs called incretins came to the fore in May 2005 when the world’s first GLP-1 agonist was approved by the US FDA.
ZYD1 has demonstrated beneficial effects in preclinical animal models on glucose reduction, HbA1c reduction and added benefits of weight loss. ZYD1 displayed a differentiated preclinical safety profile with no nausea-like symptoms and absence of antibody generation in the preclinical studies.
Source: Zydus Cadila, India